Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

被引：0
|
作者：
Laurie E. McLouth
Yue Zheng
Stephanie Smith
F. Stephen Hodi
Uma N. Rao
Gary I. Cohen
Thomas T. Amatruda
Shaker R. Dakhil
Brendan D. Curti
Ibrahim Nakhoul
Sreenivasa R. Chandana
Charles L. Bane
David E. Marinier
Sandra J. Lee
Vernon K. Sondak
John M. Kirkwood
Ahmad A. Tarhini
Lynne I. Wagner
机构：
[1] University of Kentucky,Department of Behavioral Science, College of Medicine, Markey Cancer Center
[2] Dana-Farber Cancer Institute—ECOG-ACRIN Biostatistics Center,Nancy N. and J.C. Lewis Cancer and Research Pavilion
[3] St. Joseph’s/Candler,undefined
[4] Dana-Farber Cancer Institute/Harvard Cancer Center,undefined
[5] University of Pittsburgh Cancer Institute,undefined
[6] Greater Baltimore Medical Center,undefined
[7] Minnesota Oncology,undefined
[8] Ascension Via Christi Hospitals,undefined
[9] Earle A. Chiles Research Institute,undefined
[10] Providence Cancer Institute,undefined
[11] Regional Cancer Center at Indian Path Community Hospital,undefined
[12] Cancer and Hematology Centers of Western Michigan/Cancer Research Consortium of West Michigan NCORP,undefined
[13] Good Samaritan Hospital-Dayton,undefined
[14] Gundersen Health System,undefined
[15] Moffitt Cancer Center,undefined
[16] Atrium Health Wake Forest Baptist Comprehensive Cancer Center,undefined
来源：
Quality of Life Research | 2023年 / 32卷
关键词：
Ipilimumab; Melanoma; Adjuvant therapy; Interferon; Patient-reported outcomes; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：183 / 196
页数：13
相关论文
共 18 条
  • [1] Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609
    McLouth, Laurie E.
    Zheng, Yue
    Smith, Stephanie
    Hodi, F. Stephen
    Rao, Uma N.
    Cohen, Gary, I
    Amatruda, Thomas T.
    Dakhil, Shaker R.
    Curti, Brendan D.
    Nakhoul, Ibrahim
    Chandana, Sreenivasa R.
    Bane, Charles L.
    Marinier, David E.
    Lee, Sandra J.
    Sondak, Vernon K.
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Wagner, Lynne, I
    QUALITY OF LIFE RESEARCH, 2023, 32 (01) : 183 - 196
  • [2] Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
    Jonasch, E
    Kumar, UN
    Linette, GP
    Hodi, FS
    Soiffer, RJ
    Ryan, BF
    Sober, AJ
    Mihm, MC
    Tsao, H
    Langley, RG
    Cosimi, BA
    Gadd, MA
    Tanabe, KK
    Souba, W
    Haynes, HA
    Barnhill, R
    Osteen, R
    Haluska, FG
    CANCER JOURNAL, 2000, 6 (03) : 139 - 145
  • [3] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma
    Agarwala, Sanjiv S.
    Gray, Robert J.
    Wong, Michael K. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E82 - E83
  • [4] Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors
    Minutilli, Ettore
    Feliciani, Claudio
    TUMORI JOURNAL, 2012, 98 (02): : 185 - 190
  • [5] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Li, Tao
    Jia, Dong-Dong
    Teng, Li-Song
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1334 - 1341
  • [6] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Tao Li
    Dong-Dong Jia
    Li-Song Teng
    Investigational New Drugs, 2020, 38 : 1334 - 1341
  • [7] Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
    Brandberg, Y.
    Aamdal, S.
    Bastholt, L.
    Hernberg, M.
    Stierner, U.
    von der Maase, H.
    Hansson, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (13) : 2012 - 2019
  • [8] Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
    Vanna Chiarion-Sileni
    Paola Del Bianco
    Antonella Romanini
    Michele Guida
    Adriano Paccagnella
    Maurizio Dalla Palma
    Emanuele Naglieri
    Ruggero Ridolfi
    Barbara Silvestri
    Maria Michiara
    Gian Luca De Salvo
    BMC Cancer, 6
  • [9] Toripalimab (anti-PD-1) versus high-dose interferon-a2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
    Lian, B.
    Si, L.
    Chi, Z. H.
    Sheng, X. N.
    Kong, Y.
    Wang, X.
    Tian, H.
    Li, K.
    Mao, L. L.
    Bai, X.
    Tang, B. X.
    Yan, X. Q.
    Li, S. M.
    Zhou, L.
    Dai, J.
    Tang, X. W.
    Ran, F. W.
    Yao, S.
    Guo, J.
    Cui, C. L.
    ANNALS OF ONCOLOGY, 2022, 33 (10) : 1061 - 1070
  • [10] Immunomodulatory effects of high-dose and lowdose interferon α2b in patients with high-risk resected melanoma -: The E2690 laboratory corollary of Intergroup Adjuvant Trial E1690
    Kirkwood, JM
    Richards, T
    Zarour, HM
    Sosman, J
    Ernstoff, M
    Whiteside, TL
    Ibrahim, J
    Blum, R
    Wieand, S
    Mascari, R
    CANCER, 2002, 95 (05) : 1101 - 1112
12